J 2020

The association of a reduced susceptibility to moxifloxacin in causativeClostridium(Clostridioides)difficilestrain with the clinical outcome of patients

KRUTOVA, Marcela; Vaclav CAPEK; Elka NYCOVA; Sabina VOJACKOVA; Magda BALEJOVA et al.

Základní údaje

Originální název

The association of a reduced susceptibility to moxifloxacin in causativeClostridium(Clostridioides)difficilestrain with the clinical outcome of patients

Autoři

KRUTOVA, Marcela; Vaclav CAPEK; Elka NYCOVA; Sabina VOJACKOVA; Magda BALEJOVA; Lenka GEIGEROVA; Renata TEJKALOVÁ; Lenka HAVLINOVA; Iva VAGNEROVA; Pavel CERMAK; Lenka RYSKOVA; Petr JEZEK; Dana ZAMAZALOVA; Denisa VESELA; Alice KUCHAROVA; Dana NEMCOVA; Martina CURDOVA; Otakar NYC a Pavel DREVINEK

Vydání

ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, LONDON, BMC, 2020, 2047-2994

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10606 Microbiology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.887

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116176

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

Clostridium difficileinfection; Clostridioides difficileinfection; Czech Republic; PCR ribotype 001; PCR ribotype 176; Moxifloxacin; Mortality

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 10. 8. 2020 13:07, Mgr. Tereza Miškechová

Anotace

V originále

Objectives To investigate the relationship betweenClostridium (Clostridioides) difficilestrain characteristics andC. difficileinfection (CDI) outcome. Methods Between October and December 2017, 16 hospitals collected epidemiological data according to the European Centre for Disease Prevention and Control (ECDC) surveillance protocol for CDI.C. difficileisolates were characterized by ribotyping, toxin genes detection and antibiotic susceptibility testing to metronidazole, vancomycin and moxifloxacin. Results The overall mean CDI incidence density was 4.5 [95% CI 3.6-5.3] cases per 10,000 patient-days. From the 433 CDI cases, 330 (76.2%) were healthcare-associated, 52 (12.0%) cases were community-associated or of unknown origin and 51 (11.8%) CDI cases recurrent; a complicated course of CDI was reported in 65 cases (15.0%). Eighty-eight (20.3%) of patients died and 59 of them within 30 days after the CDI diagnosis. From the 379C. difficileisolates, the most prevalent PCR ribotypes were 001 (n = 127, 33.5%) and 176 (n = 44, 11.6%). A total of 186 (49.1%) isolates showed a reduced susceptibility to moxifloxacin (> 4 mg/L) and 96.4% of them had Thr82Ile in the GyrA. Nineteen isolates revealed reduced susceptibility to metronidazole and two isolates to vancomycin (> 2 mg/L). A fatal outcome was associated with a reduced susceptibility to moxifloxacin, the advanced age of the patients and a complicated course of CDI (p<0.05). No association between ribotype, binary toxin and a reduced susceptibility to moxifloxacin and complicated course or recurrent CDI was found. Conclusions A reduced susceptibility to moxifloxacin, in causativeC. difficilestrains was associated with fatal outcome of the patients, therefore it is an important marker in surveillance of CDI.